impact factor, citescore
logo
 

Full Papers

 

Serum sCD25 is an indicator for rheumatoid arthritis-associated interstitial lung disease


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13

 

  1. Department of Rheumatism and Immunology, First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
  2. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, and Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
  3. Department of Rheumatology and Immunology, Peking University People’s Hospital, and Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
  4. Department of Rheumatology and Immunology, Peking University People’s Hospital, and Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
  5. Department of Rheumatism and Immunology, First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
  6. Department of Rheumatism and Immunology, First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
  7. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China.
  8. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China.
  9. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China.
  10. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, and Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
  11. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing; Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, and State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
  12. Department of Rheumatism and Immunology, First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China. luoli.6@163.com
  13. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, and Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China. sunxiaolin_sxl@126.com

CER16849
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 37812493 [PubMed]

Received: 21/05/2023
Accepted : 04/09/2023
In Press: 22/09/2023

Abstract

OBJECTIVES:
CD25 (IL-2Rα) is one of IL-2 receptor’s polypeptide subunits, and its soluble form is increased in patients with various inflammatory or autoimmune diseases. This study aimed to evaluate the clinical correlation of serum soluble CD25 (sCD25) with interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients.
METHODS:
294 RA patients, including 72 in the discovery cohort (15 patients with ILD, 57 patients without ILD), 222 in the validation cohort (41 patients with ILD and 181 patients without ILD), and 58 healthy controls (HCs) were recruited. High-resolution computed tomography (HRCT) scan provided evidence and patterns of RA-ILD. Serum sCD25 concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Clinical and laboratory data were recorded and the association with sCD25 was also analysed.
RESULTS:
In the discovery cohort, 16 RA-related molecules including cytokines, chemokines and functional soluble cell surface proteins were investigated. The results showed that sCD25 was significantly higher in RA-ILD than in RA-no-ILD group (p=0.004). ROC analysis also showed RA-ILD was discriminated with RA-no-ILD by sCD25 (AUC=0.695, 95% CI=0.541-0.849). Logistics regression demonstrated that sCD25 was one of the risk factors of RA-ILD. This result was further confirmed in validation cohort (p<0.001). According to the cut-off value in the discovery cohort, the sensitivity and specificity of sCD25 in RA-ILD were 51.2%, 77.3%, respectively. Compared with RA-no-ILD, serum level of sCD25 was also higher in different HRCT patterns including UIP, NSIP and RA-ILA. The ROC curves revealed sCD25 as diagnostic marker in UIP, NSIP and RA-ILA (with AUCs of 0.730, 0.761, and 0. 694, respectively, p<0.05). The result indicated that sCD25 was a biomarker for RA-ILD subtypes. Although sCD25 was not correlated with HRCT scores, it was significantly higher in consolidation pattern by HRCT.
CONCLUSIONS:
sCD25 was significantly elevated in RA-ILD (including UIP, NSIP and RA-ILA) compared to RA-no-ILD and HCs, which supports their value as a potential biomarker in RA-ILD screening and assessment.

DOI: https://doi.org/10.55563/clinexprheumatol/3iqvk3

Rheumatology Article

Rheumatology Addendum